BioGaia AB (publ)
BioGaia AB (publ) (BIOGY) Revenue
Annual & quarterly revenue history · segment & region breakdown
BIOGY · revenue · updated Jun 15, 2026
Core revenue metrics
Trailing 12 monthsBioGaia AB (publ) trailing twelve-month (TTM) revenue is $1.54B, an increase of 8.11% year-over-year from $1.54B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $1.54B | +$0.12B | +8.11% |
| 2024-12-31 | $1.42B | +$0.13B | +9.73% |
| 2023-12-31 | $1.30B | +$0.19B | +17.44% |
| 2022-12-31 | $1.10B | +$0.32B | +40.61% |
| 2021-12-31 | $0.79B | +$0.04B | +5.09% |
| 2020-12-31 | $0.75B | -$0.02B | -2.77% |
| 2019-12-31 | $0.77B | +$0.03B | +3.57% |
| 2018-12-31 | $0.74B | +$0.13B | +20.63% |
| 2017-12-31 | $0.62B | +$0.08B | +15.02% |
| 2016-12-31 | $0.53B | +$0.05B | +10.65% |
Compare revenue vs peers
Drug Manufacturers - Specialty & GenericCompare BIOGY revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income BioGaia AB (publ) receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
BioGaia AB (publ) reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in SEK.
Data sourced from BioGaia AB (publ)'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
BIOGY revenue · 4 questionsBIOGY's trailing twelve-month (TTM) revenue is $1.54B. That is an increase of 8.11% year-over-year from $1.54B in FY2025.
▸ Source: FMP · BioGaia AB (publ) SEC filings · GAAP · BioGaia AB (publ) SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 15, 2026